Advancing gene therapies, methods, and technologies for Parkinson's Disease and other neurological disorders

被引:16
作者
Fiandaca, Massimo S. [1 ]
Lonser, Russell R. [2 ]
Elder, J. Bradley [2 ]
Zabek, Miroslaw [3 ]
Bankiewicz, Krystof S. [1 ,2 ,3 ]
机构
[1] Brain Neurotherapy Bio Inc, Oakland, CA USA
[2] Ohio State Univ, Dept Neurol Surg, Wexner Med Ctr, Columbus, OH 43210 USA
[3] Brodno Mazovia Hosp, Intervent Neuro Ctr INC, Warsaw, Poland
关键词
gene therapy; convection-enhanced delivery; Parkinson's Disease; clinical neuroscience education; robotics; artificial intelligence; CONVECTION-ENHANCED DELIVERY; MULTIPLE SYSTEM ATROPHY; PROGRESSIVE SUPRANUCLEAR PALSY; TRANSGENIC MOUSE MODEL; MPTP-LESIONED PRIMATES; REAL-TIME; DOUBLE-BLIND; SUBSTANTIA-NIGRA; NATURAL-HISTORY; ALPHA-SYNUCLEIN;
D O I
10.5603/PJNNS.a2020.0046
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Vector-based intracerebral gene therapies are being used to treat specific neurodegenerative conditions such as Parkinson's Disease (PD). This review presents a basis for central nervous system (CNS) gene therapy treatments of neurodegenerative diseases such as PD, as well as the need for novel skill sets and health delivery strategies within the clinical neurosciences (neurology and neurosurgery) to meet future demand for such therapies. State of the art. Preclinical vector-based gene therapy approaches have been translated into clinical trials for PD and other neurodegenerative conditions. Unfortunately, such trials, and parallel efforts using other therapeutics, have yet to provide a breakthrough. Image-guided convection enhanced delivery (CED) optimises the parenchymal distribution of gene therapies applied within the CNS, and may ultimately provide such a breakthrough. Clinical implications. Currently, image-guided CED and gene therapy are not part of training programmes for most neurosurgeons and neurologists. As a result, few medical centres and hospitals have sufficiently experienced teams to participate in gene transfer clinical trials for PD or other neurological conditions. If CNS gene therapies prove to be efficacious for PD and/or other conditions, the demand for such treatments will overwhelm the available number of experienced clinical neuroscience teams and treatment centres. Future directions. Expanded indications and demand for CNS gene therapies will require a worldwide educational effort to supplement the training of clinical neuroscience practitioners. Initially, a limited number of Centres of Excellence will need to establish relevant educational training requirements and best practice for such therapeutic approaches. Advanced technologies, including robotics and artificial intelligence, are especially germane in this regard, and will expand the treatment teams capabilities while assisting in the safe and timely care of those afflicted.
引用
收藏
页码:220 / 231
页数:12
相关论文
共 106 条
[1]  
[Anonymous], 2014, PARKINSONISM RELAT D, DOI DOI 10.1016/S1353-8020(13)70017-8
[2]   Diagnosis and Treatment of Parkinson Disease A Review [J].
Armstrong, Melissa J. ;
Okun, Michael S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (06) :548-560
[3]   Gene Therapy for Parkinson's Disease, An Update [J].
Axelsen, Tobias M. ;
Woldbye, David P. D. .
JOURNAL OF PARKINSONS DISEASE, 2018, 8 (02) :195-215
[4]   Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC [J].
Bankiewicz, Krystof S. ;
Forsayeth, John ;
Eberling, Jamie L. ;
Sanchez-Pernaute, Rosario ;
Pivirotto, Philip ;
Bringas, John ;
Herscovitch, Peter ;
Carson, Richard E. ;
Eckelman, William ;
Reutter, Bryan ;
Cunningham, Janet .
MOLECULAR THERAPY, 2006, 14 (04) :564-570
[5]   AAV viral vector delivery to the brain by shape-conforming MR-guided infusions [J].
Bankiewicz, Krystof S. ;
Sudhakar, Vivek ;
Samaranch, Lluis ;
San Sebastian, Waldy ;
Bringas, John ;
Forsayeth, John .
JOURNAL OF CONTROLLED RELEASE, 2016, 240 :434-442
[6]   Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies [J].
Bartus, R. T. ;
Kordower, J. H. ;
Johnson, E. M., Jr. ;
Brown, L. ;
Kruegel, B. R. ;
Chu, Y. ;
Baumann, T. L. ;
Lang, A. E. ;
Olanow, C. W. ;
Herzog, C. D. .
NEUROBIOLOGY OF DISEASE, 2015, 78 :162-171
[7]   Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients [J].
Bartus, Raymond T. ;
Baumann, Tiffany L. ;
Siffert, Joao ;
Herzog, Christopher D. ;
Alterman, Ron ;
Boulis, Nicholas ;
Turner, Dennis A. ;
Stacy, Mark ;
Lang, Anthony E. ;
Lozano, Andres M. ;
Olanow, C. Warren .
NEUROLOGY, 2013, 80 (18) :1698-1701
[8]   Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease [J].
Bartus, Raymond T. ;
Brown, Lamar ;
Wilson, Alistair ;
Kruegel, Brian ;
Siffert, Joao ;
Johnson, Eugene M., Jr. ;
Kordower, Jeffrey H. ;
Herzog, Christopher D. .
NEUROBIOLOGY OF DISEASE, 2011, 44 (01) :38-52
[9]   Bioactivity of AAV2-Neurturin Gene Therapy (CERE-120): Differences Between Parkinson's Disease and Nonhuman Primate Brains [J].
Bartus, Raymond T. ;
Herzog, Christopher D. ;
Chu, Yaping ;
Wilson, Alistair ;
Brown, Lamar ;
Siffert, Joao ;
Johnson, Eugene M., Jr. ;
Olanow, C. Warren ;
Mufson, Elliott J. ;
Kordower, Jeffrey H. .
MOVEMENT DISORDERS, 2011, 26 (01) :27-36
[10]   MDS research criteria for prodromal Parkinson's disease [J].
Berg, Daniela ;
Postuma, Ronald B. ;
Adler, Charles H. ;
Bloem, Bastiaan R. ;
Chan, Piu ;
Dubois, Bruno ;
Gasser, Thomas ;
Goetz, Christopher G. ;
Halliday, Glenda ;
Joseph, Lawrence ;
Lang, Anthony E. ;
Liepelt-Scarfone, Inga ;
Litvan, Irene ;
Marek, Kenneth ;
Obeso, Jose ;
Oertel, Wolfgang ;
Olanow, C. Warren ;
Poewe, Werner ;
Stern, Matthew ;
Deuschl, Guenther .
MOVEMENT DISORDERS, 2015, 30 (12) :1600-1609